- RemoPro™ (treprostinil prodrug)
-
Product
RemoPro™
(treprostinil prodrug)Therapeutic Platform
Remodulin®Targeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Phase 1Prodrug of treprostinil that is being developed to reduce site pain associated with subcutaneous delivery of treprostinil.
LEARN MORE Close - ADVANCE Study Ralinepag (IP receptor agonist)
-
Therapeutic Platform
NCE / Novel BiologicsTargeted Indication
Pulmonary Hypertension (PH) WHO Group 1 (PAH)Status
Phase 3An IP receptor agonist that is a next-generation, once-a-day oral therapy that targets the prostacyclin pathway for patients with pulmonary arterial hypertension (PAH).
LEARN MORE Close - Genetically-Enhanced Mesenchymal stem cells (GEM)
-
Therapeutic Platform
NCE / Novel BiologicsTargeted Indication
SepsisStatus
Phase 1
Menu